PRMT7

Across TCGA pan-cancer cohorts, PRMT7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRMT7 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRMT7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRMT7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where PRMT7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.853	0.985	.003	47	view →
HNSC	OS	Median	All	0.797	0.609	.005	26	view →
PDAC	OS	Quartile	All	0.275	0.674	.014	6	view →
CCRCC	DFS	Tertile	IV	0.794	0.150	.024	3	view →
LSCC	DFS	Median	II,III,IV	0.444	0.883	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRMT7–LUAD (DFS)

Open the LUAD breakdown →